Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer

Zhai, J, Luwor, R, Ahmed, N, Escalona, R, Tan, F, Fong, C, Ratcliffe, J, Scoble, J, Drummond, C and Tran, N 2018, 'Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer', ACS Applied Materials and Interfaces, vol. 10, no. 30, pp. 25174-25185.


Document type: Journal Article
Collection: Journal Articles

Title Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer
Author(s) Zhai, J
Luwor, R
Ahmed, N
Escalona, R
Tan, F
Fong, C
Ratcliffe, J
Scoble, J
Drummond, C
Tran, N
Year 2018
Journal name ACS Applied Materials and Interfaces
Volume number 10
Issue number 30
Start page 25174
End page 25185
Total pages 12
Publisher American Chemical Society
Abstract Chemotherapy using cytotoxic agents such as paclitaxel (PTX) is one of the most effective treatments for advanced ovarian cancer. However due to non-specific targeting of the drug and the presence of toxic solvents required for dissolving PTX prior to injection, there are several serious side effects associated with this treatment. In this study, we explored self-assembled lipid based nanoparticles as PTX carriers, which were able to improve its anti-tumour efficacy against ovarian cancer. The nanoparticles were also functionalised with anti-EGFR fragments to explore the benefit of tumour active targeting. The formulated bicontinuous cubic and sponge phase nanoparticles, which were stabilised by Pluronic F127 and a lipid-PEG stabiliser, showed a high capacity of PTX loading. These PTX loaded nanoparticles also showed significantly higher cytotoxicity than a free drug formulation against HEY ovarian cancer cell lines in vitro. More importantly, the nanoparticle-based PTX treatments, with or without EGFR targeting, reduced the tumour burden by 50% when compared to PTX or non-drug control in an ovarian cancer mouse xenograft model. In addition, the PTX loaded nanoparticles were able to extend the survival of the treatment groups by up to 10 days compared to groups receiving free PTX or non-drug control. This proof of concept study has demonstrated the potential of these self-assembled lipid nanomaterials as effective drug delivery nano-carriers for poorly soluble chemotherapeutics such as PTX.
Subject Nanochemistry and Supramolecular Chemistry
Nanomaterials
Nanomedicine
Keyword(s) lipid nanoparticles
ovarian cancer
paclitaxel
drug delivery
cubosomes
sponge nanoparticles
EGFR
DOI - identifier 10.1021/acsami.8b08125
Copyright notice © 2018 American Chemical Society
ISSN 1944-8244
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 12 Abstract Views  -  Detailed Statistics
Created: Thu, 06 Dec 2018, 10:39:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us